Clinical trials: Psychosis Nos/Other
Schizophrenia, Bipolar Disorder
Integrated Care Including Assertive Community Treatment in Early Psychosis
Improvement of clinical long-term outcome through the implementation of early detection and intervention within a specialized network of integrated care (ACT and hometreatment) for adolescents and young adults with a first…
- Trial name
- ICEP (NCT02037581)
- Testing
- Early detection and Integrated Care, Standard Care
- Where
- Germany
- Volunteers
- 120 people
- Sponsor
- Universitätsklinikum Hamburg-Eppendorf
Schizophrenia Spectrum
Target Engagement for Oxytocin: Dose Ranging Study
This study will evaluate the effect of 8 doses of intranasal oxytocin or placebo on two proposed measures of target engagement in brain.
- Trial name
- R21Dose (NCT02498236)
- Testing
- Intranasal Oxytocin
- Volunteers
- 51 people
- Sponsor
- University of California, Los Angeles
Psychosis, Substance Abuse
Effect Evaluation of Individual Placement and Support (IPS)
Roughly one third of disability pensions issued in Norway are classified as mental and behavioral disorders. The proposed study aims to evaluate the effect of an innovative intervention for returning people with moderate to…
- Conditions
- Psychosis, Substance Abuse, Depression, Anxiety
- Trial name
- NCT01964092
- Testing
- Individual Placement and Support, Ordinary employment schemes
- Where
- Norway
- Volunteers
- 410 people
- Sponsor
- NORCE Norwegian Research Centre AS
Schizophrenia, First-Episode Psychosis
Using mHealth to Optimize Pharmacotherapy Regimens
This project will use a smartphone technology to improve medication prescribing for individuals with FEP. We will collect real-time symptom and functioning data via smartphones to provide prescribers and other clinical team…
- Trial name
- NCT04248517
- Testing
- mHealth Intervention
- Where
- 4 sites in United States
- Volunteers
- 23 people
- Sponsor
- New York State Psychiatric Institute
Psychosis; Schizophrenia-Like, Healthy Controls
Mechanisms of Response to Therapeutic Intervention in Clinical High Risk (CHR) for Psychosis
This study, "Psychobiological Follow-up Study of Transition from Prodrome to Early Psychosis", will be conducted in collaboration with the Shanghai Mental Health Center (SMHC) and several data processing sites in the United…
- Trial name
- NCT06542640
- Testing
- Mb-rt-fMRI-NFB, rTMS
- Where
- China
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Beth Israel Deaconess Medical Center
Schizophrenia, Schizoaffective Disorder
Minimizing Doses of Antipsychotic Medication in Older Patients With Schizophrenia.
Since side effects of antipsychotics, dopamine D2 receptor blockers, frequently occur in older patients with schizophrenia and the risk is dose dependent, clinical guidelines universally advocate the use of lower doses.
- Conditions
- Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder, Delusional Disorder
- Trial name
- NCT00716755
- Testing
- Risperidone/Olanzapine and PET scans
- Where
- Canada
- Volunteers
- 45 people
- Sponsor
- Centre for Addiction and Mental Health
Psychosis, Alcohol Use Disorder
Piloting of an Intervention to Reduce Problematic Alcohol Use in Early Phase Psychosis Patients
A focus of research for youth and Emerging Adults with early phase psychosis (EPP) has been cannabis use. However, this focus has led to overlooking the possible negative influence of another legal recreational drug, alcohol.
- Trial name
- NCT05365347
- Testing
- Cognitive Enhancement Therapy (CET)
- Where
- Canada
- Volunteers
- 24 people
- Sponsor
- Nova Scotia Health Authority
Parkinson's Disease
Psychiatric and Cognitive Manifestations of Parkinson's Disease
Parkinson's Disease (PD) is often thought of as affecting movement only. In fact, most patients also experience psychiatric and cognitive symptoms, sometimes from the disease itself, and sometimes as a side-effect of PD…
- Trial name
- NCT00360633
- Where
- United States
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- NYU Langone Health
Schizophreniform Disorders, Bipolar Disorder
REWRITALIZE Your Recovery - Evaluation of a Creative Writing Group Intervention
Health institutes call for psychosocial interventions and recovery-oriented approaches as supplement to pharmacological treatment for mental health disorders.
- Conditions
- Schizophreniform Disorders, Bipolar Disorder, Severe Depression, Ptsd
- Trial name
- REWR (NCT06251908)
- Testing
- Rewritalize, Standard mental health care
- Where
- 6 sites in Denmark
- Volunteers
- 300 people
- Sponsor
- Amager Hospital
Verbal Auditory Hallucination, Psychotic Disorders
RELATE - Efficacy and Feasibility of a Cognitive Behavioural Module for Distressing Auditory Verbal Hallucinations
Auditory hallucinations (AH) are associated with distress and reduced functioning. Psychological interventions show some promising effects on psychopathology but have been less successful in reducing AH related distress, which…
- Conditions
- Verbal Auditory Hallucination, Psychotic Disorders, Psychosis, Schizophrenia
- Trial name
- RELATE (NCT04578314)
- Testing
- Relating Therapy, Treatment as usual
- Where
- 5 sites in Germany
- Volunteers
- 85 people
- Sponsor
- University of Hamburg-Eppendorf
Psychosis
Learning Through Play Plus for Psychosis
Evidence reports that parents with schizophrenia are particularly vulnerable to parenting difficulties and also experience problems in sensitively interacting with their children.
- Trial name
- NCT06301347
- Testing
- Learning through Play Plus
- Where
- Pakistan
- Volunteers
- 90 people
- Sponsor
- Pakistan Institute of Living and Learning
Psychiatric Disorder, Drug Use
Drug Use & Infections in ViEtnam: Mental Health Intervention for INjecting Drug Users
The main objective of this study is to show that People Who Inject Drugs (PWID) suffering initially from a major depressive disorder, a psychotic disorder and/or had a suicide risk and who received a community-based psychiatric…
- Trial name
- DRIVEMINDII (NCT05886504)
- Testing
- Community-based psychiatric intervention
- Where
- Vietnam
- Volunteers
- 567 people
- Sponsor
- ANRS, Emerging Infectious Diseases
Psychotic Disorders
A Novel Treatment Approach for Self-Stigma in First Episode Psychosis
Stigma towards mental illness is one of the greatest barriers to functional recovery that people with psychotic disorders face. Internalization of stigma (self-stigma) is associated with increased depressive symptoms, treatment…
- Trial name
- BOOST (NCT03491852)
- Testing
- BOOST Intervention, Waitlist Control
- Where
- Canada
- Volunteers
- 40 people
- Sponsor
- Queen's University
Schizophrenia
Proposal To Develop A Rapid And Cost-Effective Diagnostic Test For Schizophrenia
Schizophrenia is a severe psychotic illness of unknown cause that affects 1% of the population worldwide. Currently, there is no diagnostic test for schizophrenia.
- Trial name
- NCT03781115
- Testing
- Ziprasidone, Olanzapine
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- University of Arizona
Schizophrenia, Schizoaffective Disorder
Recovery From Psychosis in Schizophrenia - The Impact of Cognitive-Behavioral Therapy
This study examines the impact of Cognitive-Behavior Therapy (CBT) on symptoms, physiological arousal, stressors, and the ways to deal with them in individuals with schizophrenia and related disorders.
- Conditions
- Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder
- Trial name
- NCT00791440
- Testing
- Cognitive-Behavior Therapy, Standard Psychiatric Treatment
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- New York State Psychiatric Institute
Psychosis
Improving Adherence to Cognitive Rehabilitation
Purpose of study is to evaluate impact of brief motivational interviewing vs. feedback on learning styles in improving attendance to cognitive training
- Trial name
- NCT02481713
- Testing
- motivational interviewing, learning style interviews
- Where
- United States
- Volunteers
- 114 people
- Sponsor
- VA Office of Research and Development
Mental Health Promotion
Designing and Evaluating a Classroom-Based Mental Health Programme for Adolescents.
This study is a mixed-methods feasibility trial designed to examine whether a universal classroom-based psychoeducational programme which covers unusual sensory experiences, psychosis, mental health stigma, and coping strategies…
- Trial name
- NCT07660874
- Testing
- School-Based Mental Health Programme
- Where
- 2 sites in United Kingdom
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Queen's University, Belfast
Schizophrenia Disorders
Investigating the Effect of Diroximel Fumarate on Glutathione in Schizophrenia
Schizophrenia is a condition that causes symptoms like delusions, hallucinations, reduced motivation and muddled thinking. It is a common, severe and disabling psychiatric illness affecting about 1/100 (1%) of people.
- Trial name
- FORTUNE (NCT06957808)
- Testing
- Diroximel fumarate (DRF)
- Where
- 3 sites in United Kingdom
- Volunteers
- 30 people
- Sponsor
- King's College London
Psychotic Disorders, Cannabis Use Disorder
Investigating the Neural Correlates of Cognitive Function in Psychosis Patients and Non-Psychiatric Controls With Cannabis Use
Cognitive impairment is well established in people with psychosis and is associated with cannabis use. The current study will investigate the neurobiological basis of cognitive change associated with 28-days of cannabis…
- Conditions
- Psychotic Disorders, Cannabis Use Disorder, Cannabis Dependence, Cannabis Use
- Trial name
- NCT05445180
- Testing
- Contingency management
- Where
- Canada
- Volunteers
- 134 people, healthy volunteers welcome
- Sponsor
- Douglas Mental Health University Institute
Dementia-related Psychosis
Relapse Prevention Study of Pimavanserin in Dementia-related Psychosis
The purpose of this study is to evaluate the efficacy of pimavanserin compared to placebo in preventing relapse of psychotic symptoms in subjects with dementia-related psychosis who responded to 12 weeks of open label…
- Trial name
- NCT03325556
- Testing
- Pimavanserin 34 mg, Pimavanserin 20 mg
- Where
- 83 sites in United States, Bulgaria and 11 more
- Volunteers
- 392 people
- Sponsor
- ACADIA Pharmaceuticals Inc.